Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer

Cohort Study on Sequential ADC Therapy in HR-positive/HER2-negative Advanced Breast Cancer

NCT07162259 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4

Impact of BMI on CDK4/6 Inhibitors Efficacy and Safety in Advanced Breast Cancer

NCT06926088 ·Status: ACTIVE_NOT_RECRUITING

Real World Study on the Efficacy and Safety of Anti-HER2 Therapy

NCT05367739 ·Status: COMPLETED

Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer

NCT07180160 ·Status: RECRUITING ·Phase: PHASE2

BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

NCT06253195 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Breast Cancer RElapsed in Patients Treated With Adjuvant CDK4/6 Inhibitors:

NCT07180693 ·Status: RECRUITING

A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.

NCT04385563 ·Status: UNKNOWN ·Phase: PHASE3

Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor

NCT06556862 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy

NCT04437160 ·Status: RECRUITING ·Phase: PHASE2

A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors

NCT06503783 ·Status: RECRUITING ·Phase: PHASE1

A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast Cancer

NCT05629949 ·Status: COMPLETED ·Phase: PHASE3

Dual Anti-HER2 Therapy (Lapatinib and Trastuzumab) Plus Chemotherapy in HER2-positive MBC

NCT04001634 ·Status: COMPLETED

A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer

NCT04796623 ·Status: COMPLETED ·Phase: PHASE2

Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer

NCT05860465 ·Status: RECRUITING ·Phase: PHASE2/PHASE3

Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer

NCT06599216 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BC

NCT05400993 ·Status: UNKNOWN ·Phase: PHASE2

A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast Cancer

NCT07173556 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2

Intensive Adjuvant Therapy for TNBC with BRCA Gene Mutation

NCT06405295 ·Status: ENROLLING_BY_INVITATION

To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer

NCT05365178 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Palbociclib Combine With Anti-HER2 Therapy in Triple Positive ABC

NCT05969184 ·Status: UNKNOWN ·Phase: PHASE2

Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer

NCT06993506 ·Status: NOT_YET_RECRUITING

Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy

NCT05978648 ·Status: RECRUITING ·Phase: PHASE2

H (Trastuzumab or Biosimilar) Combined With CDK4/6 Inhibitor + AI±OFS in the Treatment of HR+HER2+ Advanced Breast Cancer Efficacy and Safety: a Chinese Multi-center Real World Study

NCT05167643 ·Status: UNKNOWN ·Phase: NA

A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer

NCT04355520 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)

NCT06210776 ·Status: RECRUITING